Bristol Myers Squibb

New York pharmaceutical company that acquired mavacamten through its 2021 purchase of MyoKardia; Camzyos was the first cardiac myosin inhibitor FDA approved for any population, in adults, in April 2022.

bms.com

1 story

Regulatory News has published 1 story about Bristol Myers Squibb on 5 October 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 5 October 2026.

This page is generated from Regulatory News’ editorial coverage of Bristol Myers Squibb. It is not an advertisement.

Products in our coverage

CAMZYOS®mavacamten

Our coverage

1 story, newest first.

A physician in a white coat reviews a folder while smiling

For Physicians FDA's Camzyos Teen Label Requires CYP2C19 Testing Oct 5, 20269 min read Read the story

All companies